← Lakefront Biotherapeutics NV
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $129.5m |
$127.1m
-1.88%
|
$288.8m
+127.27%
|
$845.0m
+192.55%
|
$478.1m
-43.42%
|
$484.8m
+1.42%
|
$505.3m
+4.21%
|
$239.7m
-52.56%
|
$275.6m
+14.99%
|
$1.1b
+303.50%
|
$1.0b
-6.16%
|
|
| Supply revenues | — | — | — | — | — | — | — | — | $34.9m | $29.9m | — | |
| Collaboration revenues | — | — | — | — | $478.1m | $470.1m | $417.7m | $239.7m | $240.8m | $1.1b | — | |
| Revenue From Interest | — | — | — | — | — | — | — | — | $89.4m | $46.3m | — | |
| Cost of Goods and Services Sold | $119.3m |
$16.1m
-86.52%
|
$36.5m
+127.27%
|
$401.0m
+997.68%
|
$60.5m
-84.92%
|
$1.6m
-97.31%
|
$12.1m
+641.50%
|
($18.0m)
-249.20%
|
$34.9m
+293.45%
|
$29.7m
-14.71%
|
$20.8m
-30.03%
|
|
| Cost of sales | — | — | — | — | — | ($1.6m) |
($12.1m)
-641.50%
|
($18.0m)
-49.20%
|
($34.9m)
-93.45%
|
($29.7m)
+14.71%
|
$20.8m
+169.97%
|
|
| Gross Profit (Calculated) (derived) | $10.3m |
$111.0m
+982.74%
|
$252.3m
+127.27%
|
$444.0m
+75.97%
|
$417.6m
-5.95%
|
$483.2m
+15.72%
|
$493.2m
+2.07%
|
$221.7m
-55.05%
|
$240.8m
+8.61%
|
$1.1b
+349.57%
|
— | |
| Research and development | $139.6m | $218.5m | $322.9m | $427.3m | $523.7m | $491.7m | $515.1m | $241.3m | $335.5m | $459.4m | $307.6m | |
| Sales and marketing expenses | ($1.8m) | ($2.8m) | ($4.1m) | ($24.6m) | ($66.5m) | ($70.0m) | ($147.6m) | ($5.7m) | ($17.2m) | ($6.1m) | — | |
| General and administrative expenses | ($21.7m) | ($24.4m) | ($35.6m) | ($73.7m) | ($118.8m) | ($140.9m) | ($144.9m) | ($128.3m) | ($117.2m) | ($147.3m) | $103.7m | |
| General and administrative | $21.7m | $24.4m | $35.6m | $73.7m | $118.8m | $140.9m | $144.9m | $128.3m | $117.2m | $147.3m | $103.7m | |
| Operating expenses: | ||||||||||||
| Other Operating Income Expense | ($11.5m) | ($89.8m) | ($362.7m) | $370.3m | ($178.6m) | $53.7m | $46.8m | $47.3m | $40.8m | $53.5m | — | |
| Interest Expense | $47k | $936k | $780k | $1.3m | $9.4m | $11.7m | $7.0m | $1.8m | $911k | $1.0m | $1.3m | |
| Other Income | $22.1m | $28.8m | $29.0m | $50.9m | $52.2m | $53.7m | $46.8m | $47.3m | $40.8m | $53.5m | — | |
| Current Tax Expense (Income) | $466k | $218k | $584k | $1.4m | $1.1m | $2.0m | $4.1m | $5.9m | $1.3m | $792k | — | |
| Deferred Tax Expense (Income) | ($231k) | ($20k) | ($535k) | ($1.2m) | $157k | $404k | ($1.2m) | $3.7m | ($3.1m) | ($19.4m) | — | |
| Income taxes | ($235k) | ($198k) | ($50k) | ($214k) | ($1.2m) | ($2.4m) | ($2.8m) | ($9.6m) | $1.8m | $18.6m | — | |
| Net loss from continuing operations | — | — | ($32.2m) | $148.7m | ($311.0m) | ($125.4m) | ($218.0m) | ($4.0m) | ($1.3m) | $319.5m | — | |
| Basic Earnings (Loss) Per Share | $1.18 | ($2.34) | ($0.56) | $2.60 | ($4.69) | ($1.58) | ($3.32) | $3.21 | $1.12 | $4.87 | $7.42 | |
| Diluted Earnings (Loss) Per Share | $1.14 | ($2.34) | ($0.56) | $2.49 | ($4.69) | ($1.58) | ($3.32) | $3.21 | $1.12 | $4.87 | $7.42 | |
| Basic and diluted loss per share from continuing operations (in EUR per share) | — | — | ($0.62) | $2.58 | ($4.78) | ($1.91) | ($3.32) | ($0.06) | ($0.02) | $4.85 | — | |
| Weighted average number of shares - Basic (in '000 shares) | 45.7m | 49.5m | 52.1m | 58k | 65k | 65.5m | 65.7m | 65.9m | 65.9m | 65.9m | — | |
| Weighted average number of shares - Diluted (in '000 shares) | 47.3m | 49.5m | 52.1m | 60k | 68k | 131.3m | 65.7m | 65.9m | 65.9m | 65.9m | — | |
| Additional Financial Items | ||||||||||||
| Auditors Remuneration For Tax Services | — | — | — | — | — | — | — | — | $50k | $15k | — | |
| Employee Benefits Expense | $53.5m | $74.4m | $103.0m | $177.1m | $263.3m | $295.5m | $347.0m | $164.9m | $146.9m | $228.2m | — | |
| Impairment Loss Recognised In Profit Or Loss Goodwill | — | — | — | — | — | — | — | — | $0 | $69.4m | — | |
| Other Employee Expense | $9.6m | $16.5m | $27.4m | $39.1m | $9.9m | $11.2m | $18.1m | $6.7m | $9.1m | $14.6m | — | |
| Other Finance Cost | $1.7m | $30.6m | $2.7m | $60.1m | $152.8m | $30.9m | $17.7m | $2.6m | $1.7m | $2.9m | — | |
| Professional Fees Expense | — | — | — | — | — | — | — | $68k | — | — | — | |
| Profit Loss Attributable To Owners Of Parent | $54.0m | ($115.7m) | ($29.3m) | $149.8m | ($305.4m) | ($103.2m) | ($218.0m) | $211.7m | $74.1m | $320.9m | — | |
| Profit Loss Before Tax | $54.2m | ($115.5m) | ($29.2m) | $150.1m | ($309.8m) | ($123.0m) | ($215.1m) | $5.6m | ($3.1m) | $300.9m | — | |
| Profit Loss From Operating Activities | ($11.5m) | ($89.8m) | ($44.8m) | $370.3m | ($178.6m) | ($165.6m) | ($267.5m) | ($88.3m) | ($188.3m) | $295.0m | — | |
| Fair value adjustments and net exchange differences | — | — | — | — | ($116.2m) | $61.3m | $51.5m | $16.3m | $95.8m | ($39.4m) | — | |
| Other financial income | $9.9m | $4.9m | $18.3m | $21.5m | $18.7m | $70.5m | $18.6m | $80.2m | $91.1m | $48.1m | — | |
| Other financial expenses | ($1.7m) | ($30.6m) | ($2.7m) | ($60.1m) | ($152.8m) | ($30.9m) | ($17.7m) | ($2.6m) | ($1.7m) | ($2.9m) | — | |
| Net profit/(loss) (-) from discontinued operations, net of tax | — | — | $3.0m | $1.2m | $5.6m | $22.2m | ($146.6m) | $215.7m | $75.4m | $1.4m | — | |
| Net profit / (loss) (-) | $54.0m | ($115.7m) | ($29.3m) | $149.8m | ($305.4m) | ($103.2m) | ($218.0m) | $211.7m | $74.1m | $320.9m | — | |
| Owners of the parent | $54.0m | ($115.7m) | ($29.3m) | $149.8m | ($305.4m) | ($103.2m) | ($218.0m) | $211.7m | $74.1m | $320.9m | — | |
| Net Foreign Exchange Loss | — | — | — | — | $110.4m | — | — | — | — | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.